upadacitinib vs Zemprocitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: JAK1 · full Atopic Dermatitis pipeline
upadacitinib · Rinvoq
Marketed by AbbVie
NCT03607422 · Phase 3 · completed
Participants were randomized and the trial was quadruple-blinded and placebo-controlled in 912 adolescents and adults. Both co-primary endpoints -- a 75% reduction in the validated Eczema Area and Severity Index (EASI75) and clearance or near-clearance on the validated Investigator Global Assessment -- were clearly met for both upadacitinib doses versus placebo at week 16 (p<0.001 for all comparisons).
Next expected readout: November 2026 · NCT06389136 (registry estimate)
Reported efficacy
Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 (Baseline and Week 16); Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16 (Baseline and Week 16): EASI-75 response at week 16 (Measure Up 2): 60.1% (upadacitinib 15 mg) vs 72.9% (upadacitinib 30 mg) vs 13.3% (placebo). (met)
Result source: NCT03607422
Zemprocitinib
Developed by Lynk Pharmaceuticals and partners
NCT06277245 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 356 patients that measured EASI-75 skin clearance and Investigator's Global Assessment response at week 16, the standard efficacy measures for atopic dermatitis. Both the 12 mg and 24 mg doses produced large, statistically significant improvements over placebo on both endpoints.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Eczema Area and Severity Index (EASI-75) at Week 16 (Baseline and Week 16); Investigator's Global Assessment (IGA) score of 0/1 at Week 16 (Baseline and Week 16): EASI-75 at Week 16: +38.1 percentage points (12 mg) and +46.4 percentage points (24 mg) vs placebo (p<0.0001); IGA 0/1 response: +30.3 percentage points (12 mg) and +31.0 percentage points (24 mg) vs placebo (p<0.0001) (met)
Result source: NCT06277245
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | upadacitinib | Zemprocitinib |
|---|---|---|
| EASI-75 | 60.1% vs 13.3%+46.8 vs placeboNCT0360742263 other results
| —Not posted · NCT06277245 |
| IGA 0/1 with 2-point improvement | —Trial running · NCT03568318 | —Not posted · NCT06277245 |
| EASI-90 | 42.4% vs 5.4%+37 vs placeboNCT0360742214 other results
| —Not posted · NCT06277245 |
| EASI, % change | -74.1% vs -34.5%−39.6 vs placeboNCT0360742269 other results
| —Not posted · NCT06277245 |
EASI-75
- upadacitinib
- 60.1% vs 13.3%+46.8 vs placeboNCT03607422
63 other results
- 69.6% vs 16.3% NCT03569293
- 72.9% vs 13.3% NCT03607422
- 79.7% vs 16.3% NCT03569293
- 72.4% vs 62.6% NCT03738397
- 33% vs 3.6% NCT03607422
- 38.1% vs 3.6% NCT03569293
- 44% vs 3.6% NCT03607422
- 47.4% vs 3.6% NCT03569293
- 69% vs 13.3% NCT03607422
- 74.6% vs 12.1% NCT03569293
- 37.9% vs 6.7% NCT03607422
- 39.7% vs 3.4% NCT03569293
- 73.4% vs 13.3% NCT03607422
- 84.5% vs 12.1% NCT03569293
- 53.2% vs 6.7% NCT03607422
- 55.8% vs 3.4% NCT03569293
- 44.3% vs 18.2% NCT03738397
- 52.4% vs 9.8% NCT02925117
- 52.4% vs 7.3% NCT02925117
- 69% vs 9.8% NCT02925117
- 81% vs 7.3% NCT02925117
- 28.6% vs 9.8% NCT02925117
- 31% vs 7.3% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 0% vs 11.1% NCT02925117
- 12.5% vs 11.1% NCT02925117
- 100% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 80% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 66.7% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 66.7% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 85.7% vs 100% NCT02925117
- 33.3% vs 100% NCT02925117
- 33.3% vs 100% NCT02925117
- 12.5% vs 11.1% NCT02925117
- 20% vs 11.1% NCT02925117
- 25% vs 11.1% NCT02925117
- 0% vs 100% NCT02925117
- 33.3% vs 100% NCT02925117
- 0% vs 11.1% NCT02925117
- 9.1% vs 11.1% NCT02925117
- Zemprocitinib
- —Not posted · NCT06277245
IGA 0/1 with 2-point improvement
- upadacitinib
- —Trial running · NCT03568318
- Zemprocitinib
- —Not posted · NCT06277245
EASI-90
- upadacitinib
- 42.4% vs 5.4%+37 vs placeboNCT03607422
14 other results
- 53.1% vs 8.1% NCT03569293
- 58.5% vs 5.4% NCT03607422
- 65.8% vs 8.1% NCT03569293
- 48.3% vs 1.7% NCT03607422
- 47.6% vs 3.4% NCT03569293
- 62% vs 1.7% NCT03607422
- 74.1% vs 3.4% NCT03569293
- 61.6% vs 40.3% NCT03738397
- 26.2% vs 2.4% NCT02925117
- 26.2% vs 0% NCT02925117
- 50% vs 2.4% NCT02925117
- 45.2% vs 0% NCT02925117
- 14.3% vs 2.4% NCT02925117
- 9.5% vs 0% NCT02925117
- Zemprocitinib
- —Not posted · NCT06277245
EASI, % change
- upadacitinib
- -74.1% vs -34.5%−39.6 vs placeboNCT03607422
69 other results
- -80.2% vs -40.7% NCT03569293
- -84.7% vs -34.5% NCT03607422
- -87.7% vs -40.7% NCT03569293
- -77.8% vs -42.2% NCT03607422
- -82.1% vs -43.5% NCT03569293
- -84.8% vs -42.2% NCT03607422
- -89.4% vs -43.5% NCT03569293
- -61.7% vs -23% NCT02925117
- -74.4% vs -23% NCT02925117
- -39.4% vs -23% NCT02925117
- 617.5% vs -37.7% NCT02925117
- 99.3% vs -37.7% NCT02925117
- 614% vs -37.3% NCT02925117
- 130.2% vs -37.3% NCT02925117
- 614.6% vs -35.8% NCT02925117
- 104.1% vs -35.8% NCT02925117
- 613.8% vs -29.8% NCT02925117
- 104.1% vs -29.8% NCT02925117
- 608.8% vs -31.2% NCT02925117
- 154.1% vs -31.2% NCT02925117
- 613.3% vs -2.3% NCT02925117
- 151.7% vs -2.3% NCT02925117
- 607.3% vs 13.5% NCT02925117
- 72.6% vs 13.5% NCT02925117
- 582.3% vs 50.7% NCT02925117
- 65.7% vs 50.7% NCT02925117
- -65.4% vs -17.5% NCT02925117
- -84.6% vs -37.7% NCT02925117
- 769.7% vs -37.7% NCT02925117
- 39% vs -37.7% NCT02925117
- -90.3% vs -37.3% NCT02925117
- 787.8% vs -37.3% NCT02925117
- 24.4% vs -37.3% NCT02925117
- -91.4% vs -35.8% NCT02925117
- 802.1% vs -35.8% NCT02925117
- 63.6% vs -35.8% NCT02925117
- -90.1% vs -29.8% NCT02925117
- 799.5% vs -29.8% NCT02925117
- -13.3% vs -29.8% NCT02925117
- -92% vs -31.2% NCT02925117
- 778.9% vs -31.2% NCT02925117
- 140.6% vs -31.2% NCT02925117
- -69.6% vs 13.5% NCT02925117
- -73.8% vs 50.7% NCT02925117
- -82.8% vs -17.5% NCT02925117
- -83.1% vs -2.3% NCT02925117
- 771.5% vs -2.3% NCT02925117
- -28.8% vs -2.3% NCT02925117
- -67.5% vs 13.5% NCT02925117
- 898.5% vs 13.5% NCT02925117
- 181.5% vs -2.3% NCT02925117
- 63.5% vs -2.3% NCT02925117
- 189.6% vs 13.5% NCT02925117
- 59% vs 13.5% NCT02925117
- 186% vs 50.7% NCT02925117
- 79.1% vs 50.7% NCT02925117
- -43.7% vs -17.5% NCT02925117
- 11.8% vs 50.7% NCT02925117
- 791.5% vs 50.7% NCT02925117
- 170.7% vs -37.7% NCT02925117
- 69.1% vs -37.7% NCT02925117
- 201.4% vs -37.3% NCT02925117
- 77.7% vs -37.3% NCT02925117
- 179.9% vs -35.8% NCT02925117
- 71.8% vs -35.8% NCT02925117
- 189.1% vs -29.8% NCT02925117
- 74.4% vs -29.8% NCT02925117
- 200.9% vs -31.2% NCT02925117
- 77.6% vs -31.2% NCT02925117
- Zemprocitinib
- —Not posted · NCT06277245
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. upadacitinib: 4 of 4 rows · Zemprocitinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | upadacitinib |
|---|---|
| Dropout rate | —15 mga NCT03607422 · Phase 3 show 48 more results—15 mg NCT03607422 · Phase 3 5.2%15 mg QD NCT03607422 · Phase 3 —15 mg NCT03607422 · Phase 3 —15 mg NCT03607422 · Phase 3 4.1%15 mg QD NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 3.2%30 mg QD NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 4.5%30 mg QD NCT03607422 · Phase 3 —15 mg NCT03569293 · Phase 3 —15 mg QD NCT03569293 · Phase 3 0%15 mg QD NCT03569293 · Phase 3 —15 mg NCT03569293 · Phase 3 —15 mg NCT03569293 · Phase 3 3.3%15 mg QD NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 —30 mg QD NCT03569293 · Phase 3 0%30 mg QD NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 4.9%30 mg QD NCT03569293 · Phase 3 5.2%15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —15 mg then 30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 2.6%30 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg then 15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 10.5%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 16.5%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 8.8%30 mg QD NCT03738397 · Phase 3 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence 11.9%15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 7.1%30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence 26.2%7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —15 mga NCT03607422 · Phase 3 show 48 more results—15 mg NCT03607422 · Phase 3 3.4%15 mg QD NCT03607422 · Phase 3 —15 mg NCT03607422 · Phase 3 —15 mg NCT03607422 · Phase 3 1.2%15 mg QD NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 0%30 mg QD NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 0.4%30 mg QD NCT03607422 · Phase 3 —15 mg NCT03569293 · Phase 3 —15 mg QD NCT03569293 · Phase 3 0%15 mg QD NCT03569293 · Phase 3 —15 mg NCT03569293 · Phase 3 —15 mg NCT03569293 · Phase 3 0.4%15 mg QD NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 —30 mg QD NCT03569293 · Phase 3 0%30 mg QD NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 1.6%30 mg QD NCT03569293 · Phase 3 —15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —15 mg then 30 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg then 15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 1.7%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 4.7%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 2%30 mg QD NCT03738397 · Phase 3 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence 2.4%15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 4.8%30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence 7.1%7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 15.4%15 mga NCT03607422 · Phase 3 show 48 more results10.9%15 mg NCT03607422 · Phase 3 3.4%15 mg QD NCT03607422 · Phase 3 10.6%15 mg NCT03607422 · Phase 3 16.6%15 mg NCT03607422 · Phase 3 1.2%15 mg QD NCT03607422 · Phase 3 13.8%30 mg NCT03607422 · Phase 3 16.9%30 mg NCT03607422 · Phase 3 0%30 mg QD NCT03607422 · Phase 3 17.3%30 mg NCT03607422 · Phase 3 17.4%30 mg NCT03607422 · Phase 3 2.8%30 mg QD NCT03607422 · Phase 3 3.3%15 mg NCT03569293 · Phase 3 12.5%15 mg QD NCT03569293 · Phase 3 3.1%15 mg QD NCT03569293 · Phase 3 14.7%15 mg NCT03569293 · Phase 3 14.3%15 mg NCT03569293 · Phase 3 2.1%15 mg QD NCT03569293 · Phase 3 22.2%30 mg NCT03569293 · Phase 3 10.9%30 mg QD NCT03569293 · Phase 3 0%30 mg QD NCT03569293 · Phase 3 20%30 mg NCT03569293 · Phase 3 18.4%30 mg NCT03569293 · Phase 3 3.3%30 mg QD NCT03569293 · Phase 3 3.5%15 mg NCT05507580 · Phase 4 · registry result, not featured evidence 1.4%15 mg NCT05507580 · Phase 4 · registry result, not featured evidence 0.7%15 mg then 30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 0%30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 0.8%30 mg then 15 mg NCT05507580 · Phase 4 · registry result, not featured evidence 0%30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 5.9%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 5.5%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 4.1%30 mg QD NCT03738397 · Phase 3 · registry result, not featured evidence 2.4%15 mg NCT02925117 · Phase 2 · registry result, not featured evidence 2.4%15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence 6.1%30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 0%30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 4.8%7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence 4.8%7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 15 mga covid-19 23.1% (placebo 0%) acne 19.2% (placebo 3.3%) dermatitis atopic 19.2% (placebo 13.3%) NCT03607422 · Phase 3 show 38 more results15 mg covid-19 27.3% (placebo 0%) upper respiratory tract infection 21.8% (placebo 1.7%) acne 18.2% (placebo 3.3%) NCT03607422 · Phase 3 15 mg QD acne 10.3% (placebo 3.3%) upper respiratory tract infection 10.3% (placebo 1.7%) oropharyngeal pain 6.9% (placebo 0%) NCT03607422 · Phase 3 15 mg covid-19 31.7% (placebo 0%) acne 19.2% (placebo 3.3%) blood creatine phosphokinase increased 17.3% (placebo 1.7%) NCT03607422 · Phase 3 15 mg covid-19 31.9% (placebo 0%) dermatitis atopic 17.9% (placebo 13.3%) upper respiratory tract infection 14.4% (placebo 1.7%) NCT03607422 · Phase 3 15 mg QD acne 12.8% (placebo 3.3%) headache 7% (placebo 3.3%) nasopharyngitis 6.2% (placebo 3.3%) NCT03607422 · Phase 3 30 mg covid-19 41.4% (placebo 0%) acne 34.5% (placebo 3.3%) dermatitis atopic 24.1% (placebo 13.3%) NCT03607422 · Phase 3 30 mg covid-19 32.2% (placebo 0%) blood creatine phosphokinase increased 18.6% (placebo 1.7%) acne 11.9% (placebo 3.3%) NCT03607422 · Phase 3 30 mg QD acne 14.5% (placebo 3.3%) blood creatine phosphokinase increased 9.7% (placebo 1.7%) headache 8.1% (placebo 3.3%) NCT03607422 · Phase 3 30 mg covid-19 39.4% (placebo 0%) acne 25% (placebo 3.3%) dermatitis atopic 15.4% (placebo 13.3%) NCT03607422 · Phase 3 30 mg covid-19 29.8% (placebo 0%) blood creatine phosphokinase increased 18.3% (placebo 1.7%) dermatitis atopic 14.9% (placebo 13.3%) NCT03607422 · Phase 3 30 mg QD acne 15% (placebo 3.3%) nasopharyngitis 8.1% (placebo 3.3%) headache 6.5% (placebo 3.3%) NCT03607422 · Phase 3 15 mg covid-19 20% (placebo 0%) acne 16.7% (placebo 1.6%) blood creatine phosphokinase increased 16.7% (placebo 3.3%) NCT03569293 · Phase 3 15 mg QD covid-19 25% (placebo 0%) upper respiratory tract infection 21.9% (placebo 8.2%) blood creatine phosphokinase increased 12.5% (placebo 3.3%) NCT03569293 · Phase 3 15 mg QD acne 14.1% (placebo 1.6%) blood creatine phosphokinase increased 7.8% (placebo 3.3%) headache 7.8% (placebo 3.3%) NCT03569293 · Phase 3 15 mg covid-19 38.2% (placebo 0%) dermatitis atopic 18.6% (placebo 3.3%) upper respiratory tract infection 18.6% (placebo 8.2%) NCT03569293 · Phase 3 15 mg covid-19 28.6% (placebo 0%) nasopharyngitis 16.5% (placebo 1.6%) dermatitis atopic 16% (placebo 3.3%) NCT03569293 · Phase 3 15 mg QD upper respiratory tract infection 9.6% (placebo 8.2%) nasopharyngitis 7.9% (placebo 1.6%) acne 5.4% (placebo 1.6%) NCT03569293 · Phase 3 30 mg acne 37% (placebo 1.6%) upper respiratory tract infection 33.3% (placebo 8.2%) dermatitis atopic 29.6% (placebo 3.3%) NCT03569293 · Phase 3 30 mg QD covid-19 35.9% (placebo 0%) acne 28.1% (placebo 1.6%) upper respiratory tract infection 28.1% (placebo 8.2%) NCT03569293 · Phase 3 30 mg QD acne 15.6% (placebo 1.6%) upper respiratory tract infection 12.5% (placebo 8.2%) blood creatine phosphokinase increased 7.8% (placebo 3.3%) NCT03569293 · Phase 3 30 mg covid-19 38.1% (placebo 0%) acne 22.9% (placebo 1.6%) blood creatine phosphokinase increased 17.1% (placebo 3.3%) NCT03569293 · Phase 3 30 mg covid-19 35.1% (placebo 0%) acne 18.9% (placebo 1.6%) dermatitis atopic 18% (placebo 3.3%) NCT03569293 · Phase 3 30 mg QD acne 16.5% (placebo 1.6%) upper respiratory tract infection 12.8% (placebo 8.2%) nasopharyngitis 11.5% (placebo 1.6%) NCT03569293 · Phase 3 15 mg acne 7% nasopharyngitis 5.7% upper respiratory tract infection 3.5% NCT05507580 · Phase 4 · registry result, not featured evidence 15 mg nasopharyngitis 11.1% dermatitis atopic 8.3% upper respiratory tract infection 6.9% NCT05507580 · Phase 4 · registry result, not featured evidence 15 mg then 30 mg dermatitis atopic 16% nasopharyngitis 4.2% acne 2.8% NCT05507580 · Phase 4 · registry result, not featured evidence 30 mg acne 13.8% nasopharyngitis 9.1% dermatitis atopic 3.9% NCT05507580 · Phase 4 · registry result, not featured evidence 30 mg then 15 mg dermatitis atopic 12% nasopharyngitis 7.5% acne 6% NCT05507580 · Phase 4 · registry result, not featured evidence 30 mg dermatitis atopic 16.5% acne 6.6% eczema 5.5% NCT05507580 · Phase 4 · registry result, not featured evidence 30 mg acne 20.5% covid-19 13.4% blood creatine phosphokinase increased 13% NCT04195698 · Phase 3 · registry result, not featured evidence 30 mg acne 22.9% dermatitis atopic 19.1% blood creatine phosphokinase increased 14.8% NCT04195698 · Phase 3 · registry result, not featured evidence 30 mg QD acne 18.7% dermatitis atopic 10.5% blood creatine phosphokinase increased 7.6% NCT03738397 · Phase 3 · registry result, not featured evidence 15 mg upper respiratory tract infection 16.7% (placebo 5.4%) dermatitis atopic 11.9% (placebo 2.2%) nasopharyngitis 11.9% (placebo 1.1%) NCT02925117 · Phase 2 · registry result, not featured evidence 15 mg upper respiratory tract infection 11.9% (placebo 5.4%) nasopharyngitis 9.5% (placebo 1.1%) blood creatine phosphokinase increased 7.1% (placebo 3.2%) NCT02925117 · Phase 2 · registry result, not featured evidence 30 mg upper respiratory tract infection 22.8% (placebo 5.4%) dermatitis atopic 19.3% (placebo 2.2%) acne 11.4% (placebo 1.1%) NCT02925117 · Phase 2 · registry result, not featured evidence 30 mg acne 14.3% (placebo 1.1%) upper respiratory tract infection 11.9% (placebo 5.4%) blood creatine phosphokinase increased 9.5% (placebo 3.2%) NCT02925117 · Phase 2 · registry result, not featured evidence 7.5 mg upper respiratory tract infection 16.7% (placebo 5.4%) dermatitis atopic 14.3% (placebo 2.2%) acne 9.5% (placebo 1.1%) NCT02925117 · Phase 2 · registry result, not featured evidence 7.5 mg upper respiratory tract infection 16.7% (placebo 5.4%) dermatitis atopic 11.9% (placebo 2.2%) acne 9.5% (placebo 1.1%) NCT02925117 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
upadacitinib
show 63 more results
show 7 more results
show 38 more results
show 14 more results
show 7 more results
show 8 more results
show 7 more results
show 69 more results
show 7 more results
show 7 more results
show 13 more results
show 7 more results
+ 25 further endpoints in the CSV export.
Rheumatoid Arthritis
Shared mechanism: JAK1 · full Rheumatoid Arthritis pipeline
upadacitinib · Rinvoq
Marketed by AbbVie
NCT02675426 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 661 patients using two validated rheumatoid arthritis disease-activity measures as co-primary endpoints, and both upadacitinib doses produced significantly higher response rates than placebo on both measures (all comparisons p<0.001).
Next expected readout: March 2027 · NCT07636057 (registry estimate)
Reported efficacy
Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Non-inferiority) (Baseline and Week 12): Change from baseline DAS28-CRP at week 12: -2.52 (95% CI -2.66 to -2.37) upadacitinib vs -2.00 (95% CI -2.14 to -1.85) abatacept; upadacitinib met primary non-inferiority and key secondary superiority endpoints. (met)
Result source: NCT03086343
Zemprocitinib
Developed by Lynk Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | upadacitinib | Zemprocitinib |
|---|---|---|
| ACR20 | 63.8% vs 35.7%+28.1 vs placeboNCT0267542649 other results
| —Not posted · NCT06276998 |
| ACR50 | 52.1% vs 28.3%vs MethotrexateNCT0270687341 other results
| —Not posted · NCT06276998 |
| ACR70 | 20.8% vs 5.9%+14.9 vs placeboNCT0267542641 other results
| —Not posted · NCT06276998 |
| DAS28-CRP remission | 48.3% vs 18.5%vs MethotrexateNCT0270687322 other results
| —Not posted · NCT06276998 |
| HAQ-DI, change | -0.6 vs -0.3−0.3 vs placeboNCT0267542632 other results
| —Not posted · NCT06276998 |
| Modified Sharp score, change | 0.1 vs 0.7vs MethotrexateNCT027068734 other results
| —Not posted · NCT06276998 |
ACR20
- upadacitinib
- 63.8% vs 35.7%+28.1 vs placeboNCT02675426
49 other results
- 64.6% vs 28.4% NCT02706847
- 71.6% vs 31.4% NCT02955212
- 66.2% vs 35.7% NCT02675426
- 56.4% vs 28.4% NCT02706847
- 83.7% vs 42.9% NCT02720523
- 80% vs 42.9% NCT02720523
- 75.5% vs 42.9% NCT02720523
- 67.7% vs 41.2% NCT02706951
- 75.7% vs 54.1% NCT02706873
- 71.2% vs 41.2% NCT02706951
- 77.1% vs 54.1% NCT02706873
- 22.2% vs 8.6% NCT02675426
- 27.4% vs 10.7% NCT02706847
- 25.4% vs 5.9% NCT02955212
- 28.3% vs 8.6% NCT02675426
- 24.8% vs 10.7% NCT02706847
- 24.5% vs 8.2% NCT02720523
- 34% vs 8.2% NCT02720523
- 30.6% vs 8.2% NCT02720523
- 78.9% vs 58.6% NCT02706873
- 78% vs 58.6% NCT02706873
- 85.2% vs 57.1% NCT02706873
- 78.6% vs 57.1% NCT02706873
- 85.5% vs 57.1% NCT02706873
- 81.6% vs 50% NCT02066389
- 76.6% vs 50% NCT02066389
- 70.9% vs 35.2% NCT01960855
- 81.6% vs 50% NCT02066389
- 72.7% vs 35.2% NCT01960855
- 73.5% vs 50% NCT02066389
- 63.5% vs 35.2% NCT01960855
- 64.6% vs 50% NCT02066389
- 55.6% vs 35.2% NCT01960855
- 41.5% vs 47.4% NCT03682705
- 39% vs 36.8% NCT03682705
- 29.3% vs 42.1% NCT03682705
- 24.4% vs 21.1% NCT03682705
- 30.8% vs 47.4% NCT03682705
- 30.8% vs 36.8% NCT03682705
- 23.1% vs 42.1% NCT03682705
- 12.8% vs 21.1% NCT03682705
- 64.5% vs 47.4% NCT03682705
- 64.5% vs 36.8% NCT03682705
- 51.6% vs 42.1% NCT03682705
- 45.2% vs 21.1% NCT03682705
- 34.1% vs 47.4% NCT03682705
- 39% vs 36.8% NCT03682705
- 22% vs 42.1% NCT03682705
- 14.6% vs 21.1% NCT03682705
- Zemprocitinib
- —Not posted · NCT06276998
ACR50
- upadacitinib
- 52.1% vs 28.3%vs MethotrexateNCT02706873
41 other results
- 56.4% vs 28.3% NCT02706873
- 38% vs 14.9% NCT02675426
- 34.1% vs 11.8% NCT02706847
- 40.8% vs 8.3% NCT02955212
- 43.4% vs 14.9% NCT02675426
- 35.8% vs 11.8% NCT02706847
- 65.3% vs 16.3% NCT02720523
- 58% vs 16.3% NCT02720523
- 40.8% vs 16.3% NCT02720523
- 60.3% vs 33.4% NCT02706873
- 41.9% vs 15.3% NCT02706951
- 65.6% vs 33.4% NCT02706873
- 52.1% vs 15.3% NCT02706951
- 66.7% vs 21.4% NCT02706873
- 71.4% vs 21.4% NCT02706873
- 60% vs 21.4% NCT02706873
- 29.3% vs 21.1% NCT03682705
- 19.5% vs 5.3% NCT03682705
- 17.1% vs 10.5% NCT03682705
- 4.9% vs 0% NCT03682705
- 43.8% vs 19.6% NCT02066389
- 12.8% vs 21.1% NCT03682705
- 12.8% vs 5.3% NCT03682705
- 2.6% vs 10.5% NCT03682705
- 0% vs 0% NCT03682705
- 44.7% vs 19.6% NCT02066389
- 40% vs 17% NCT01960855
- 45.2% vs 21.1% NCT03682705
- 41.9% vs 5.3% NCT03682705
- 19.4% vs 10.5% NCT03682705
- 16.1% vs 0% NCT03682705
- 50% vs 19.6% NCT02066389
- 43.6% vs 17% NCT01960855
- 49% vs 19.6% NCT02066389
- 38.5% vs 17% NCT01960855
- 17.1% vs 21.1% NCT03682705
- 7.3% vs 5.3% NCT03682705
- 4.9% vs 10.5% NCT03682705
- 0% vs 0% NCT03682705
- 39.6% vs 19.6% NCT02066389
- 24.1% vs 17% NCT01960855
- Zemprocitinib
- —Not posted · NCT06276998
ACR70
- upadacitinib
- 20.8% vs 5.9%+14.9 vs placeboNCT02675426
41 other results
- 11.6% vs 6.5% NCT02706847
- 21.3% vs 3.6% NCT02955212
- 26.5% vs 5.9% NCT02675426
- 23% vs 6.5% NCT02706847
- 34.7% vs 2% NCT02720523
- 28% vs 2% NCT02720523
- 20.4% vs 2% NCT02720523
- 44.5% vs 18.5% NCT02706873
- 22.6% vs 2.8% NCT02706951
- 32.5% vs 14% NCT02706873
- 49.7% vs 18.5% NCT02706873
- 33% vs 2.8% NCT02706951
- 36.9% vs 14% NCT02706873
- 51.9% vs 0% NCT02706873
- 64.3% vs 0% NCT02706873
- 34.5% vs 0% NCT02706873
- 14.6% vs 15.8% NCT03682705
- 4.9% vs 0% NCT03682705
- 4.9% vs 0% NCT03682705
- 2.4% vs 0% NCT03682705
- 25% vs 6.5% NCT02066389
- 5.1% vs 15.8% NCT03682705
- 2.6% vs 0% NCT03682705
- 2.6% vs 0% NCT03682705
- 0% vs 0% NCT03682705
- 27.7% vs 6.5% NCT02066389
- 21.8% vs 3.6% NCT01960855
- 25.8% vs 15.8% NCT03682705
- 17.7% vs 0% NCT03682705
- 9.7% vs 0% NCT03682705
- 8.1% vs 0% NCT03682705
- 16% vs 6.5% NCT02066389
- 21.8% vs 3.6% NCT01960855
- 30.6% vs 6.5% NCT02066389
- 26.9% vs 3.6% NCT01960855
- 9.8% vs 15.8% NCT03682705
- 0% vs 0% NCT03682705
- 0% vs 0% NCT03682705
- 0% vs 0% NCT03682705
- 23.4% vs 6.5% NCT02066389
- 13% vs 3.6% NCT01960855
- Zemprocitinib
- —Not posted · NCT06276998
DAS28-CRP remission
- upadacitinib
- 48.3% vs 18.5%vs MethotrexateNCT02706873
22 other results
- 50% vs 18.5% NCT02706873
- 30.8% vs 10% NCT02675426
- 29.6% vs 5.3% NCT02955212
- 28.3% vs 10% NCT02675426
- 57.1% vs 6.1% NCT02720523
- 50% vs 6.1% NCT02720523
- 36.7% vs 6.1% NCT02720523
- 28.1% vs 8.3% NCT02706951
- 30% vs 13.3% NCT03086343
- 40.5% vs 8.3% NCT02706951
- 70.4% vs 17.9% NCT02706873
- 82.1% vs 17.9% NCT02706873
- 67.3% vs 17.9% NCT02706873
- 19.5% vs 10.5% NCT03682705
- 22.4% vs 14.9% NCT02066389
- 7.7% vs 10.5% NCT03682705
- 42.9% vs 14.9% NCT02066389
- 32.3% vs 10.5% NCT03682705
- 34% vs 14.9% NCT02066389
- 38.8% vs 14.9% NCT02066389
- 9.8% vs 10.5% NCT03682705
- 36.7% vs 14.9% NCT02066389
- Zemprocitinib
- —Not posted · NCT06276998
HAQ-DI, change
- upadacitinib
- -0.6 vs -0.3−0.3 vs placeboNCT02675426
32 other results
- -0.4 vs -0.2 NCT02706847
- -0.6 vs -0.2 NCT02955212
- -0.5 vs -0.3 NCT02675426
- -0.4 vs -0.2 NCT02706847
- -0.5 vs -0.1 NCT02720523
- -0.5 vs -0.1 NCT02720523
- -0.4 vs -0.1 NCT02720523
- -0.9 vs -0.6 NCT02706873
- -0.7 vs -0.3 NCT02706951
- -0.8 vs -0.5 NCT02706873
- -0.9 vs -0.6 NCT02706873
- -0.7 vs -0.3 NCT02706951
- -0.9 vs -0.5 NCT02706873
- -0.9 vs -0.2 NCT02706873
- -0.9 vs -0.2 NCT02706873
- -0.8 vs -0.2 NCT02706873
- -0.3 vs -0.3 NCT03682705
- -0.3 vs -0.2 NCT03682705
- -0.1 vs -0.4 NCT03682705
- -0.1 vs -0.2 NCT03682705
- -0.1 vs -0.3 NCT03682705
- -0.1 vs -0.2 NCT03682705
- -0.1 vs -0.4 NCT03682705
- -0.1 vs -0.2 NCT03682705
- -0.5 vs -0.3 NCT03682705
- -0.5 vs -0.2 NCT03682705
- -0.4 vs -0.4 NCT03682705
- -0.3 vs -0.2 NCT03682705
- -0.2 vs -0.3 NCT03682705
- -0.1 vs -0.2 NCT03682705
- -0.2 vs -0.4 NCT03682705
- -0.2 vs -0.2 NCT03682705
- Zemprocitinib
- —Not posted · NCT06276998
Modified Sharp score, change
- upadacitinib
- 0.1 vs 0.7vs MethotrexateNCT02706873
4 other results
- 0.1 vs 0.7 NCT02706873
- 0.2 vs 2.6 NCT02706873
- 0.2 vs 2.6 NCT02706873
- 0.9 vs 2.6 NCT02706873
- Zemprocitinib
- —Not posted · NCT06276998
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Zemprocitinib: no structured comparison results are available for Rheumatoid Arthritis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. upadacitinib: 4 of 4 rows · Zemprocitinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | upadacitinib |
|---|---|
| Dropout rate | —15 mga NCT02675426 · Phase 3 show 55 more results—15 mg NCT02675426 · Phase 3 —15 mg NCT02675426 · Phase 3 3.6%15 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 8.2%30 mg NCT02675426 · Phase 3 —15 mg NCT02706873 · Phase 3 · monotherapy 12.6%15 mg NCT02706873 · Phase 3 —15 mg NCT02706873 · Phase 3 · monotherapy —15 mg NCT02706873 · Phase 3 · monotherapy 14%30 mg NCT02706873 · Phase 3 —30 mg NCT02706873 · Phase 3 · monotherapy —30 mg NCT02706873 · Phase 3 · monotherapy 7.3%7.5 mg NCT02706873 · Phase 3 —7.5 mg NCT02706873 · Phase 3 · monotherapy —7.5 mg NCT02706873 · Phase 3 · monotherapy —15 mg QD NCT03086343 · Phase 3 —15 mg QD NCT03086343 · Phase 3 —30 mg QD NCT03086343 · Phase 3 —30 mg QD NCT03086343 · Phase 3 7.4%15 mg NCT02706951 · Phase 3 —15 mg NCT02706951 · Phase 3 —15 mg NCT02706951 · Phase 3 4.7%30 mg NCT02706951 · Phase 3 —30 mg NCT02706951 · Phase 3 4.8%15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 9.7%30 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 —15 mg NCT02955212 · Phase 3 · registry result, not featured evidence —15 mg NCT02955212 · Phase 3 · registry result, not featured evidence —15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 4.1%15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 12%30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 0%7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —12 mg BID/30 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence —6 mg BID/15 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence 7.3%60 mg NCT03682705 · Phase 2 · registry result, not featured evidence 12.8%20 mg NCT03682705 · Phase 2 · registry result, not featured evidence 6.5%15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination 14.6%5 mg NCT03682705 · Phase 2 · registry result, not featured evidence 10%24 mg QD NCT02066389 · Phase 2 · registry result, not featured evidence 14%18 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 6%12 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 12%6 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%3 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 9.1%18 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 7.3%12 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 16.4%6 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 7.3%3 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —15 mga NCT02675426 · Phase 3 show 55 more results—15 mg NCT02675426 · Phase 3 —15 mg NCT02675426 · Phase 3 1.4%15 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 4.1%30 mg NCT02675426 · Phase 3 —15 mg NCT02706873 · Phase 3 · monotherapy 5.7%15 mg NCT02706873 · Phase 3 —15 mg NCT02706873 · Phase 3 · monotherapy —15 mg NCT02706873 · Phase 3 · monotherapy 3.5%30 mg NCT02706873 · Phase 3 —30 mg NCT02706873 · Phase 3 · monotherapy —30 mg NCT02706873 · Phase 3 · monotherapy 5.5%7.5 mg NCT02706873 · Phase 3 —7.5 mg NCT02706873 · Phase 3 · monotherapy —7.5 mg NCT02706873 · Phase 3 · monotherapy —15 mg QD NCT03086343 · Phase 3 —15 mg QD NCT03086343 · Phase 3 —30 mg QD NCT03086343 · Phase 3 —30 mg QD NCT03086343 · Phase 3 2.3%15 mg NCT02706951 · Phase 3 —15 mg NCT02706951 · Phase 3 —15 mg NCT02706951 · Phase 3 1.4%30 mg NCT02706951 · Phase 3 —30 mg NCT02706951 · Phase 3 0.6%15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 7.3%30 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 —15 mg NCT02955212 · Phase 3 · registry result, not featured evidence —15 mg NCT02955212 · Phase 3 · registry result, not featured evidence —15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 2%15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 10%30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 0%7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —12 mg BID/30 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence —6 mg BID/15 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence 2.4%60 mg NCT03682705 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03682705 · Phase 2 · registry result, not featured evidence 1.6%15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination 2.4%5 mg NCT03682705 · Phase 2 · registry result, not featured evidence 2%24 mg QD NCT02066389 · Phase 2 · registry result, not featured evidence 10%18 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%12 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%6 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%3 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 3.6%18 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 3.6%12 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 10.9%6 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 0%3 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 28.1%15 mga NCT02675426 · Phase 3 show 55 more results4.5%15 mg NCT02675426 · Phase 3 10.6%15 mg NCT02675426 · Phase 3 —15 mg NCT02675426 · Phase 3 3.2%30 mg NCT02675426 · Phase 3 31.8%30 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 15.5%15 mg NCT02706873 · Phase 3 · monotherapy —15 mg NCT02706873 · Phase 3 5%15 mg NCT02706873 · Phase 3 · monotherapy 21.5%15 mg NCT02706873 · Phase 3 · monotherapy —30 mg NCT02706873 · Phase 3 6.4%30 mg NCT02706873 · Phase 3 · monotherapy 22.6%30 mg NCT02706873 · Phase 3 · monotherapy —7.5 mg NCT02706873 · Phase 3 9.1%7.5 mg NCT02706873 · Phase 3 · monotherapy 23.6%7.5 mg NCT02706873 · Phase 3 · monotherapy 4%15 mg QD NCT03086343 · Phase 3 23.6%15 mg QD NCT03086343 · Phase 3 19%30 mg QD NCT03086343 · Phase 3 35.3%30 mg QD NCT03086343 · Phase 3 5.1%15 mg NCT02706951 · Phase 3 10.7%15 mg NCT02706951 · Phase 3 29.9%15 mg NCT02706951 · Phase 3 2.8%30 mg NCT02706951 · Phase 3 24.1%30 mg NCT02706951 · Phase 3 —15 mg NCT02706847 · Phase 3 15.2%15 mg NCT02706847 · Phase 3 5.5%15 mg NCT02706847 · Phase 3 36.9%15 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 7.3%30 mg NCT02706847 · Phase 3 29.6%30 mg NCT02706847 · Phase 3 17.1%15 mg NCT02955212 · Phase 3 · registry result, not featured evidence 7.1%15 mg NCT02955212 · Phase 3 · registry result, not featured evidence 21.9%15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 2%15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 27.3%30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 10%30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 13.8%7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 2%7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 22.5%12 mg BID/30 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence 13.8%6 mg BID/15 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence 0%60 mg NCT03682705 · Phase 2 · registry result, not featured evidence 5.1%20 mg NCT03682705 · Phase 2 · registry result, not featured evidence 0%15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination 7.3%5 mg NCT03682705 · Phase 2 · registry result, not featured evidence 4.1%24 mg QD NCT02066389 · Phase 2 · registry result, not featured evidence 6%18 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%12 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 4%6 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 0%3 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 1.8%18 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 0%12 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 3.6%6 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 3.6%3 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 15 mga upper respiratory tract infection 19.8% (placebo 4.1%) nasopharyngitis 18.5% (placebo 4.1%) urinary tract infection 17% (placebo 3.6%) NCT02675426 · Phase 3 show 48 more results15 mg nausea 6.8% (placebo 3.2%) nasopharyngitis 5.4% (placebo 4.1%) upper respiratory tract infection 5.4% (placebo 4.1%) NCT02675426 · Phase 3 15 mg covid-19 8.9% (placebo 0%) rheumatoid arthritis 4.5% (placebo 4.5%) fall 2.8% (placebo 0.5%) NCT02675426 · Phase 3 30 mg nasopharyngitis 5.9% (placebo 4.1%) upper respiratory tract infection 5.5% (placebo 4.1%) headache 3.7% (placebo 5.4%) NCT02675426 · Phase 3 30 mg upper respiratory tract infection 17.8% (placebo 4.1%) urinary tract infection 14.3% (placebo 3.6%) nasopharyngitis 14% (placebo 4.1%) NCT02675426 · Phase 3 15 mg covid-19 10.5% rheumatoid arthritis 9.4% urinary tract infection 7.2% NCT02706873 · Phase 3 · monotherapy 15 mg upper respiratory tract infection 6.3% nasopharyngitis 5.7% nausea 5.7% NCT02706873 · Phase 3 · monotherapy 15 mg upper respiratory tract infection 15.5% nasopharyngitis 15.1% urinary tract infection 13.6% NCT02706873 · Phase 3 · monotherapy 30 mg blood creatine phosphokinase increased 10.8% upper respiratory tract infection 7.3% urinary tract infection 5.7% NCT02706873 · Phase 3 · monotherapy 30 mg blood creatine phosphokinase increased 16.2% nasopharyngitis 16.2% hypertension 14% NCT02706873 · Phase 3 · monotherapy 15 mg QD upper respiratory tract infection 8.6% nasopharyngitis 7.3% urinary tract infection 6.6% NCT03086343 · Phase 3 30 mg QD hypertension 23.5% upper respiratory tract infection 23.5% bronchitis 17.6% NCT03086343 · Phase 3 15 mg urinary tract infection 4.6% upper respiratory tract infection 4.1% blood creatine phosphokinase increased 2.3% NCT02706951 · Phase 3 15 mg nasopharyngitis 17.6% rheumatoid arthritis 14.2% urinary tract infection 13.5% NCT02706951 · Phase 3 30 mg urinary tract infection 4.7% blood creatine phosphokinase increased 4.2% upper respiratory tract infection 2.8% NCT02706951 · Phase 3 30 mg blood creatine phosphokinase increased 18.6% urinary tract infection 15.1% upper respiratory tract infection 14.8% NCT02706951 · Phase 3 15 mg rheumatoid arthritis 9.4% (placebo 5.9%) urinary tract infection 8% (placebo 5.9%) back pain 5.8% (placebo 2.4%) NCT02706847 · Phase 3 15 mg urinary tract infection 9.8% (placebo 5.9%) upper respiratory tract infection 7.9% (placebo 7.7%) bronchitis 4.3% (placebo 2.4%) NCT02706847 · Phase 3 15 mg upper respiratory tract infection 31.4% (placebo 7.7%) urinary tract infection 18.2% (placebo 5.9%) nasopharyngitis 14.4% (placebo 6.5%) NCT02706847 · Phase 3 30 mg upper respiratory tract infection 6.7% (placebo 7.7%) nasopharyngitis 5.5% (placebo 6.5%) urinary tract infection 5.5% (placebo 5.9%) NCT02706847 · Phase 3 30 mg upper respiratory tract infection 27.9% (placebo 7.7%) urinary tract infection 20.4% (placebo 5.9%) nasopharyngitis 17.1% (placebo 6.5%) NCT02706847 · Phase 3 15 mg upper respiratory tract infection 20.2% (placebo 6.5%) alanine aminotransferase increased 9.3% (placebo 1.2%) blood creatine phosphokinase increased 9% (placebo 0%) NCT02955212 · Phase 3 · registry result, not featured evidence 15 mg upper respiratory tract infection 9.5% (placebo 6.5%) alanine aminotransferase increased 5.3% (placebo 1.2%) anaemia 0% (placebo 0%) NCT02955212 · Phase 3 · registry result, not featured evidence 15 mg nasopharyngitis 54.7% (placebo 10.2%) herpes zoster 14.1% (placebo 2%) influenza 14.1% (placebo 4.1%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 15 mg nasopharyngitis 12.2% (placebo 10.2%) liver function test increased 6.1% (placebo 0%) constipation 4.1% (placebo 0%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 30 mg nasopharyngitis 43.9% (placebo 10.2%) constipation 15.2% (placebo 0%) herpes zoster 15.2% (placebo 2%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 30 mg nasopharyngitis 18% (placebo 10.2%) blood creatine phosphokinase increased 6% (placebo 0%) headache 6% (placebo 0%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 7.5 mg nasopharyngitis 53.8% (placebo 10.2%) stomatitis 20% (placebo 6.1%) hypertension 12.3% (placebo 0%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 7.5 mg nasopharyngitis 10.2% (placebo 10.2%) hypertension 6.1% (placebo 0%) stomatitis 6.1% (placebo 6.1%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 12 mg BID/30 mg QD upper respiratory tract infection 20.3% urinary tract infection 15% herpes zoster 11.2% NCT02049138 · Phase 2 · registry result, not featured evidence 6 mg BID/15 mg QD upper respiratory tract infection 9.9% nasopharyngitis 9.5% urinary tract infection 9.5% NCT02049138 · Phase 2 · registry result, not featured evidence 60 mg urinary tract infection 9.8% (placebo 0%) diarrhoea 7.3% (placebo 0%) rheumatoid arthritis 7.3% (placebo 10.5%) NCT03682705 · Phase 2 · registry result, not featured evidence 20 mg rheumatoid arthritis 7.7% (placebo 10.5%) upper respiratory tract infection 7.7% (placebo 5.3%) alopecia 5.1% (placebo 0%) NCT03682705 · Phase 2 · registry result, not featured evidence 15 mg/60 mg upper respiratory tract infection 6.5% (placebo 5.3%) arthralgia 1.6% (placebo 5.3%) cough 1.6% (placebo 0%) NCT03682705 · Phase 2 · registry result, not featured evidence · combination 5 mg rheumatoid arthritis 7.3% (placebo 10.5%) upper respiratory tract infection 4.9% (placebo 5.3%) urinary tract infection 4.9% (placebo 0%) NCT03682705 · Phase 2 · registry result, not featured evidence 24 mg QD nasopharyngitis 6.1% (placebo 2%) back pain 2% (placebo 0%) blood creatine phosphokinase increased 2% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 18 mg BID blood creatine phosphokinase increased 4% (placebo 0%) nasopharyngitis 4% (placebo 2%) cough 2% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 12 mg BID influenza 8% (placebo 0%) nasopharyngitis 8% (placebo 2%) blood creatine phosphokinase increased 6% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 6 mg BID back pain 6% (placebo 0%) nasopharyngitis 4% (placebo 2%) cough 2% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 3 mg BID headache 4% (placebo 2%) back pain 2% (placebo 0%) cough 2% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 18 mg BID urinary tract infection 12.7% (placebo 3.6%) blood creatine phosphokinase increased 9.1% (placebo 0%) constipation 7.3% (placebo 0%) NCT01960855 · Phase 2 · registry result, not featured evidence 12 mg BID upper respiratory tract infection 7.3% (placebo 1.8%) headache 5.5% (placebo 1.8%) leukopenia 5.5% (placebo 0%) NCT01960855 · Phase 2 · registry result, not featured evidence 6 mg BID headache 5.5% (placebo 1.8%) hyperlipidaemia 3.6% (placebo 1.8%) constipation 1.8% (placebo 0%) NCT01960855 · Phase 2 · registry result, not featured evidence 3 mg BID nausea 7.3% (placebo 1.8%) arthralgia 5.5% (placebo 0%) headache 5.5% (placebo 1.8%) NCT01960855 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
upadacitinib
show 49 more results
show 21 more results
show 38 more results
show 32 more results
show 16 more results
show 22 more results
show 23 more results
show 3 more results
show 4 more results
show 41 more results
show 41 more results
show 4 more results
+ 18 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: upadacitinib's landscape · Zemprocitinib's landscape